Innoviva Price to Book Ratio 2010-2024 | INVA
Historical price to book ratio values for Innoviva (INVA) over the last 10 years. The current price to book ratio for Innoviva as of January 31, 2025 is 1.77.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Innoviva Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2025-01-31 |
18.64 |
|
1.75 |
| 2024-09-30 |
19.31 |
$10.68 |
1.81 |
| 2024-06-30 |
16.40 |
$10.64 |
1.54 |
| 2023-12-31 |
16.04 |
$10.66 |
1.50 |
| 2023-09-30 |
12.99 |
$9.75 |
1.33 |
| 2023-06-30 |
12.73 |
$8.51 |
1.50 |
| 2023-03-31 |
11.25 |
$8.53 |
1.32 |
| 2022-12-31 |
13.25 |
$8.18 |
1.62 |
| 2024-03-31 |
15.24 |
$11.21 |
1.36 |
| 2022-09-30 |
11.61 |
$9.19 |
1.26 |
| 2022-06-30 |
14.76 |
$8.11 |
1.82 |
| 2022-03-31 |
19.35 |
$7.93 |
2.44 |
| 2021-12-31 |
17.25 |
$7.56 |
2.28 |
| 2021-09-30 |
16.71 |
$7.08 |
2.36 |
| 2021-06-30 |
13.41 |
$5.67 |
2.37 |
| 2021-03-31 |
11.95 |
$6.87 |
1.74 |
| 2020-12-31 |
12.39 |
$5.99 |
2.07 |
| 2020-09-30 |
10.45 |
$5.28 |
1.98 |
| 2020-06-30 |
13.98 |
$4.86 |
2.88 |
| 2020-03-31 |
11.76 |
$4.01 |
2.94 |
| 2019-12-31 |
14.16 |
$3.38 |
4.19 |
| 2019-09-30 |
10.54 |
$2.80 |
3.76 |
| 2019-06-30 |
14.56 |
$2.44 |
5.98 |
| 2019-03-31 |
14.03 |
$1.98 |
7.10 |
| 2018-12-31 |
17.45 |
$1.57 |
11.09 |
| 2018-09-30 |
15.24 |
$-1.07 |
-14.22 |
| 2018-06-30 |
13.80 |
$-1.53 |
-9.03 |
| 2018-03-31 |
16.67 |
$-2.10 |
-7.94 |
| 2017-12-31 |
14.19 |
$-2.38 |
-5.96 |
| 2017-09-30 |
14.12 |
$-2.06 |
-6.84 |
| 2017-06-30 |
12.80 |
$-2.71 |
-4.72 |
| 2017-03-31 |
13.83 |
$-3.06 |
-4.52 |
| 2016-12-31 |
10.70 |
$-3.26 |
-3.29 |
| 2016-09-30 |
10.99 |
$-3.36 |
-3.27 |
| 2016-06-30 |
10.53 |
$-3.26 |
-3.23 |
| 2016-03-31 |
12.59 |
$-3.20 |
-3.93 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.183B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
